Examkin

Question

Difficulty: HardGastroenterology and Hepatology

A 45-year-old man is evaluated in the gastroenterology clinic for a 6-month history of severe, burning epigastric pain and chronic, large-volume watery diarrhea. The pain frequently awakens him at night and has not improved despite taking a high-dose proton pump inhibitor (PPI) for the past 8 weeks. Upper endoscopy performed two weeks ago revealed thickened gastric folds and multiple deep ulcerations in the stomach, duodenal bulb, and descending duodenum. Gastric biopsies obtained during the procedure were negative for Helicobacter pylori. Vital signs are within normal limits, and routine laboratory studies show a normal comprehensive metabolic panel. The physician strongly suspects a neuroendocrine etiology for this patient's condition. Arrange the following diagnostic steps in the most appropriate chronological sequence for evaluating this patient's suspected condition.

  1. 1Discontinue the current proton pump inhibitor therapy
  2. 2Measure fasting serum gastrin concentration
  3. 3Perform a secretin stimulation test
  4. 4Perform somatostatin receptor scintigraphy or endoscopic ultrasound

Answer

The correct diagnostic sequence is to first discontinue the proton pump inhibitor, then measure fasting serum gastrin, follow up with a secretin stimulation test if needed, and finally perform tumor localization imaging.
The diagnostic algorithm for Zollinger-Ellison syndrome (ZES) requires strict biochemical confirmation prior to anatomic localization. Because proton pump inhibitors (PPIs) cause a profound decrease in gastric acid, they stimulate reactive gastrin secretion from normal gastric G-cells, leading to false-positive results. Therefore, the essential first step is to discontinue the PPI. Following an appropriate washout period, a fasting serum gastrin is measured. If this level is equivocal (typically between 110 and 1,000 pg/mL) rather than definitively diagnostic (>1,000 pg/mL with gastric pH <2), a secretin stimulation test is utilized. In a normal physiologic state, secretin inhibits gastrin release; however, it paradoxically increases gastrin secretion from gastrinoma cells. Only after biochemical confirmation is definitively complete should the clinician pursue imaging, such as somatostatin receptor scintigraphy (OctreoScan) or endoscopic ultrasound (EUS), to localize the tumor for potential surgical resection.

Step-by-Step Solution

1
Discontinue PPI therapy.
Gastric acid secretion recovers, preventing false-positive gastrin elevation.
PPI-induced achlorhydria causes reactive hypergastrinemia, which confounds biochemical screening.
2
Measure fasting serum gastrin.
Provides the baseline gastrin concentration.
This is the primary biochemical screening test for Zollinger-Ellison syndrome.
3
Perform a secretin stimulation test.
Paradoxical rise in gastrin (>200 pg/mL) confirms the diagnosis.
Required to differentiate a gastrinoma from other causes of hypergastrinemia when initial levels are non-diagnostic (<1,000 pg/mL).
4
Perform tumor localization imaging (EUS or somatostatin receptor scintigraphy).
Identifies the anatomic location of the gastrinoma (often in the gastrinoma triangle).
Anatomic localization is strictly reserved until after the biochemical diagnosis is secure to avoid chasing incidental non-functioning neuroendocrine tumors.

Key Concept

The algorithmic diagnostic sequence for Zollinger-Ellison syndrome (Gastrinoma)
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic